OverviewSuggest Edit

Scynexis is engaged in drug discovery, development and manufacturing projects in various areas and in manufacturing projects, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The Company also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing.
HQJersey City, NJ, US
Employee Ratings2.6

Latest Updates

Employees (est.) (Mar 2020)27(+13%)
Revenue (FY, 2019)$121 K(-52%)
Share Price (Feb 2021)$8.9 (-3%)
Cybersecurity ratingAMore

Key People/Management at Scynexis

Marco Taglietti

Marco Taglietti

President and Chief Executive Officer, Director
Guy MacDonald

Guy MacDonald

Chairman of the Board
David Angulo

David Angulo

Chief Medical Officer
Armando Anido

Armando Anido

Eric Francois

Eric Francois

Chief Financial Officer
Steven C. Gilman

Steven C. Gilman

Show more

Scynexis Office Locations

Scynexis has an office in Jersey City
Jersey City, NJ, US (HQ)
1 Evertrust Plz
Show all (1)

Scynexis Financials and Metrics

Scynexis Revenue

Scynexis's revenue was reported to be $121 k in FY, 2019

Net income (Q3, 2020)


EBIT (Q3, 2020)


Market capitalization (8-Feb-2021)


Closing stock price (8-Feb-2021)


Cash (30-Sept-2020)



Scynexis's current market capitalization is $172.6 m.
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses


Current Assets

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020



Accounts Receivable


Prepaid Expenses


Current Assets

USDQ1, 2014


-0.1 x


1.2 x

Financial Leverage

-0.1 x
Show all financial metrics

Scynexis Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Scynexis Online and Social Media Presence

Embed Graph

Scynexis Blogs

World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019

"Oral ibrexafungerp has demonstrated nonclinical and clinical success in difficult-to-treat fungal infections" "Preclinical data shows oral ibrexafungerp's potential role in controlling Candida auris" "Supporting data shows the potential of oral ibrexafungerp as a broad-spectrum antifungal, allowing…

SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development

­­­­Expertise in antifungal drug development and medical affairs Appointment strengthens the SCYNEXIS team in anticipation of ibrexafungerp's potential approval and commercial launch JERSEY CITY, N.J., June 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering…

SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections

New in vivo studies support potential use of ibrexafungerp in skin and invasive infections caused by multidrug-resistant pathogen, Candida auris New chronic nonclinical toxicity studies demonstrate ibrexafungerp's favorable safety profile, supporting its long-term administration Ibrexafungerp to be …

SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update

Continued advancement of VVC program, including completed favorable embryo-fetal safety profile, further supports a potential first NDA submission of oral ibrexafungerp in the second half of 2020 Positive clinical data from ongoing FURI and CARES studies reinforce the potential role of oral ibrexafu…

SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)

Complete regulatory embryo-fetal toxicology package shows no adverse fetal effects caused by ibrexafungerp Confirmed antifungal activity of ibrexafungerp against a variety of Candida strains resistant to fluconazole Favorable embryo-fetal safety profile and sustained activity, including against resi…

SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call

Global fungal infection thought leaders to participate Call to be held April 15, 2019 at 4:15 p.m. ET JERSEY CITY, N.J., April 15, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infectio…
Show more

Scynexis Frequently Asked Questions

  • When was Scynexis founded?

    Scynexis was founded in 1999.

  • Who are Scynexis key executives?

    Scynexis's key executives are Marco Taglietti, Guy MacDonald and David Angulo.

  • How many employees does Scynexis have?

    Scynexis has 27 employees.

  • What is Scynexis revenue?

    Latest Scynexis annual revenue is $121 k.

  • What is Scynexis revenue per employee?

    Latest Scynexis revenue per employee is $4.5 k.

  • Who are Scynexis competitors?

    Competitors of Scynexis include NGM Biopharmaceuticals, Pharmacy Alliance and Apotex Pharmachem.

  • Where is Scynexis headquarters?

    Scynexis headquarters is located at 1 Evertrust Plz, Jersey City.

  • Where are Scynexis offices?

    Scynexis has an office in Jersey City.

  • How many offices does Scynexis have?

    Scynexis has 1 office.